Also known as: Sequel Med Tech
Sequel Med Tech is a private medical technology company developing transformative insulin delivery technologies for people with diabetes. Its twiist automated insulin delivery system aims to simplify diabetes management and broaden access to advanced delivery options.
Arecor said it is in talks on a broader AT278 partnership as it targets a phase II trial start in the second half of 2026. The company also cited FDA feedback, Ligand financing and year-end cash of £6.1 million.
Sequel Med Tech and Senseonics announced full U.S. availability of the twiist Automated Insulin Delivery System integrated with the Eversense 365 CGM, the world's only one-year continuous glucose monitor, for people with type 1 diabetes.
